IMVT - Immunovant, Inc.
27.08
0.370 1.366%
Share volume: 1,244,127
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$26.71
0.37
0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
| Report Date | 11-07-2024 | 08-06-2024 | 11-07-2024 | 02-06-2025 | 05-29-2025 | 08-11-2025 | 11-10-2025 | 02-06-2026 | |
| Assets | |||||||||
| Total Assets | 666.365 M | 589.678 M | 515.707 M | 420.932 M | 776.222 M | 661.440 M | 582.959 M | 1.052 B | |
| Current Assets | 665.770 M | 589.047 M | 507.372 M | 412.541 M | 767.662 M | 651.763 M | 573.546 M | 1.043 B | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 635.365 M | 560.005 M | 472.941 M | 374.685 M | 713.971 M | 598.912 M | 521.870 M | 994.525 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 462.000 K | 565.000 K | 671.000 K | 752.000 K | 844.000 K | 737.000 K | 632.000 K | 531.000 K | |
| Other Assets | 133.000 K | 66.000 K | 7.664 M | 7.639 M | 7.716 M | 8.940 M | 8.781 M | 8.922 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 666.365 M | 589.678 M | 515.707 M | 420.932 M | 776.222 M | 661.440 M | 582.959 M | 1.052 B | |
| Total liabilities | 48.608 M | 45.018 M | 66.653 M | 68.315 M | 68.775 M | 52.900 M | 63.254 M | 66.257 M | |
| Total current liabilities | 48.608 M | 45.018 M | 66.653 M | 68.315 M | 68.775 M | 52.900 M | 63.254 M | 66.257 M | |
| Accounts Payable | 7.155 M | 11.035 M | 20.727 M | 19.816 M | 17.656 M | 7.843 M | 6.916 M | 8.616 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 617.757 M | 544.660 M | 449.054 M | 352.617 M | 707.447 M | 608.540 M | 519.705 M | 986.135 M | |
| Common stock | 1.442 B | 1.456 B | 1.469 B | 1.483 B | 1.946 B | 1.967 B | 2.005 B | 2.582 B | |
| Retained earnings | -825.683 M | -912.833 M | -1.022 B | -1.133 B | -1.240 B | -1.360 B | -1.487 B | -1.597 B |